ConductScience.org, home
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
API referenceFor AI assistants

Trial · NCT04524689

Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab23
Overall StudySTARTEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab2
Overall StudySTARTEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin6
Overall StudySTARTEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin1
Overall StudySTARTEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed22
Overall StudySTARTEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed3
Overall StudyCOMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab7
Overall StudyCOMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab1
Overall StudyCOMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin4
Overall StudyCOMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin1
Overall StudyCOMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed16
Overall StudyCOMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed2
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab16
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab1
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin2
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin0
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed6
Overall StudyNOT COMPLETEDTusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04524689/flow

API referenceFor AI assistants